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Abstract
Introduction and hypothesis This study evaluates the
relevance of the tape position and change in shape (tape
functionality) under in vivo conditions for mid-term
outcome.
Methods Changes in the sonographic tension-free vaginal
tape (TVT) position relative to the percentage urethral
length and the tape–urethra distance were determined after
6 and 48 months in 41 women with stress urinary
incontinence.
Results At 48 months, 76% (31/41) of women were cured,
17% (7/41) were improved, and 7% (3/41) were failures.
Disturbed bladder voiding was present in 12% (5/41), de
novo urge incontinence in 7% (3/41). The median TVT
position was at 63% of urethral length. Median tape–urethra
distance was 2.7 mm, ranging from 2.9 mm in continent
patients without complications to 1.1 mm in those with
obstructive complications. Patients with postoperative urine
loss had a median distance of 3.9 mm. The tape was
stretched at rest and C-shaped during straining in 15 of 41
women (37%) at 48 months (all continent). Patients with
this tape functionality at 6 months were also cured at
48 months in 86% of cases (19/22), and only 14% (3/22)
showed recurrent incontinence.
Conclusions Mid-term data suggest an optimal outcome if
the tape is positioned at least 2 mm from the urethra at the
junction of the middle and distal thirds. Patients with
optimal tape functionality at 6 months are likely to show
mid-term therapeutic success.
Keywords Introitalultrasound.Mid-term outcome.Stress
urinaryincontinence.Tapeposition.Tapetension→tape
functionality.Tension-freevaginaltape(TVT)
Introduction
Surgical insertion of tension-free vaginal tape (TVT) aims
at stabilizing the mid-third of the urethra. This therapeutic
option for women with urinary incontinence has been
extensively studied, but there is one aspect that has so far
not received any scientific attention, namely how the
elastic sling behaves in vivo during straining. Ultrasound
(US) is an easy to perform imaging modality that allows
in vivo evaluation of the TVT. Sonographic evaluation of
the lower urinary tract has become an established
component of the urogynecologic diagnostic workup of
women presenting with urinary incontinence. US is a
straightforward, fast, and reproducible dynamic imaging
tool [1–5].
The aim of the study presented here is to summarize
mid-term data on the relevance of the sonographically
determined tape position and changes in TVT shape for
the outcome of surgery and the occurrence of complica-
tions. Another aim is to identify intra-individual tape
changes in this patient population and discuss their
potential implications.
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Our mid-term study is based on the data obtained in 41
women with clinically and urodynamically proven stress
urinary incontinence (SUI) who underwent TVT insertion
at the Dept. of Urogynecology of en-Süd-Klinikum
Schwelm (Germany) between April 2000 and June 2002
using the standard technique [6, 7]. The patients underwent
routine postoperative examinations. All factors considered
to possibly affect outcome at the time of examination were
carefully documented to be available for later evaluation of
treatment success in the setting of quality assurance. In this
sense, data were obtained in a prospective manner.
The patients had a median age of 58.8 years (range, 38–
82) and a median weight of 71.3 kg (range, 55–100) with a
median body mass index (BMI) of 26.2 kg/m
2 (range, 20–
35). The median number of spontaneous deliveries was 2.0
(range, 0–5). One patient had a history of vacuum
extraction, while none of the patients had had a cesarean
section.
Since all study patients underwent routine investigations
and introital US was used for quality assurance purposes, the
study was exempted from formal Ethics Committee approval
by the Institutional Review Board of the University of
Göttingen, Germany. Nevertheless, all patients were informed
about the study and consented to participate.
The patients’ incontinence symptoms were verified
preoperatively by clinical examinations and urodynamic
testing. In addition, the patients underwent a 1-h pad test,
documented their drinking and voiding habits in a voiding
diary, and were administered a self-completion detailed
urinary incontinence questionnaire according to Ulmsten et
al. [7] The patients assessed their subjective degree of
suffering on a ten-point visual analogue scale (VAS)
ranging from 0 (no suffering due to incontinence) to 10
(unbearable suffering due to incontinence).
Standardized introital ultrasound was performed after
6 months using an Ultramark HDI C9-5 ICT system (ATL,
Hamburg, Germany) and after 48 months using a Toshiba
Aplio [3]. Both follow-up ultrasound examinations were
performed by the same examiners, using comparable
ultrasound equipment and parameter settings. In addition,
parallel measurements were performed to preclude system-
atic errors. With the patient in the semi-sitting position and
a standardized bladder filling volume of 300 ml, the
ultrasound probe (3.6–8.3-MHz vaginal probe, 160° ultra-
sound beam angle) was positioned in the area of the vaginal
opening at the level of the external urethral orifice exerting
the slightest pressure possible and aligning the axis of the
probe to the patient’s long body axis. Postoperative US
examinations were performed with a sonographically
verified bladder filling volume of about 300 ml. With the
probe in this position, median sagittal US views comprise
the urinary bladder, urethra, suburethral vagina, pubic
symphysis, and the interpubic disk.
The following parameters were analyzed: the position of
the TVT (center of the tape) relative to the percentage
urethral length, L, on median sagittal views and the shortest
distance, A, in millimeters (mm) between the hypoechoic
urethra and the tape. Urethral length was measured on a
median sagittal scan with 300-ml bladder filling from the
bladder neck (anterior edge) to the distal end of the
hypoechoic urethra. The distance was measured by drawing
a perpendicular line from the border of the hypoechoic
periurethral muscle and mucosa to the tape, which has high
echogenicity on sonography.
Changes in tape shape (tape functionality) during
Valsalva’s maneuver were documented by video. At rest,
the hyperechoic TVT lies parallel to the hypoechoic
urethra. This TVT shape is referred to as “stretched out”.
A typical change in TVT shape is observed during
Valsalva’s maneuver. The dorsocaudal movement of the
bladder neck and urethra causes the latter to assume a C-
shape and press against the TVT. The tape being elastic
adjusts its shape to the bent urethra and briefly becomes
what we refer to as “C-shaped” as well. The maximum
change observed in this setting served to divide the patients
into three groups:
Group I The tape is “stretched out” at rest and becomes
“C-shaped” during straining.
Group II The tape lies parallel to the urethral lumen at rest
and during straining.
Group III The tape is already “C-shaped” at rest and does
not change upon straining.
All TVT operations in the study population were
performed by two urogynecologists following the manu-
facturer’s recommendations [6].
Postoperatively, the patients’ symptoms were followed
up by history, clinical examination, and introital US
between the second and fifth postoperative day, at 6 and
at 48 months. Additional urodynamic testing was per-
formed in patients with therapeutic failure. Voiding dys-
function was defined as symptoms of stranguria and a
postmicturition residual volume of greater than 100 ml at
48-months follow-up (median, 15 ml; range, 0–150) [8].
The outcome of TVT treatment was evaluated using a
combination of objective and subjective criteria modified
from the suggestions made by Ulmsten et al. in 1999 [7].
Patients were classified as cured if the postoperative cough
test was negative, the 1-h pad test was negative (<2 g
difference), and the degree of subjective suffering improved
to over 90% (VAS score of 0 or 1). Criteria for
improvement were involuntary loss of only a few drops of
urine during straining or a 1-h pad test with a weight
difference of 2–10 g (or a reduction of over 50%), and an
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score of 2 or 3) . All other patients were classified as
therapeutic failures (even if they showed marked improve-
ment of one of the parameters compared with their
preoperative status).
Statistical analysis was done using the Wilcoxon–Mann–
Whitney (WMW) test for continuous parameters and
Pearson’s chi
2 test for categorical data. Statistical signifi-
cance was assumed at a p-value <0.05. Statistical tests were
performed and graphic representations were generated
using STATISTICA 8.0.725 (StatSoft, Inc. 2008).
Results
Table 1 lists the cure rates at 6- and 48-month follow-ups.
Comparison of outcome at 6 and 48 months reveals that
86% (30/35) of the women initially classified as cured were
still continent at the 48-month follow-up, 9% (3/35)
showed improvement, and secondary therapeutic failure
was noted in 6% (2/35).
During the 48-month follow-up period, the median tape
position (percentage relative to urethral length) changed
from 65.0% (range, 22.0–87.0) to 62.5% (range, 15.7–
77.0). The tape–urethra distance significantly decreased
from 3.9 mm (range, 1.0–8.9) to 2.7 mm (range, 0.0–8.9)
(p<0.001). The optimal tape position determined at 6-
month follow-up was at 50–80% of the urethral length with
a tape–urethra distance of 3–5 mm. A significant ventroc-
ranial shift of the tape was noted at 48 months as shown in
Fig. 1. At 48 months, success rates were highest for tape
positions between 40% and 70% of the urethral length and
a tape distance of 2–5 mm. A tape position outside this
range significantly decreased the likelihood of being cured
(p<0.001).
The data summarized in Table 2 demonstrate that
ventrocranial shift of the tape affects tape function. An
earlier study of our group revealed that tape functionality
correlates with outcome at 6 months postoperatively [9];
the data of the present analysis show that a similar
correlation also exists at 48-month follow-up. The cure
rate was 100% (15/15) in women with a stretched tape at
rest and a C-shape during straining (Group I). In contrast,
39% of the patients with tape shapes according to Groups II
and III were incontinent (p<0.001). Figure 2 shows the
changes in tape shape in Groups I–III (tape functionality)
by baseline tape position. Outcome was best in Group I,
where most patients had a tape position between 40% and
70% of the urethral length. In Group II, the tape–urethra
distance was typically 4 mm or more. Nevertheless, an
unchanged tape (parallel to the urethra at rest and during
straining) was observed in two women despite a small
tape–urethra distance and was attributed to an immobile,
rigid urethra. A change in tape shape according to Group III
Cured (48months) Improved (48months) Failure (48months) Total
Cured (6 months) 30 3 2 35
Improved (6 months) 1 3 0 4
Failure (6 months) 0 1 1 2
Total 31 7 3 41
Table 1 Changes in outcome
between 6 and 48 months after
surgery
Fig. 1 Outcome 48 months after TVT insertion according to tape
position relative to the urethra and tape distance from the urethra. The
optimal tape position, which was found to be at 50–80% of the
urethral length with a tape–urethra distance of 3–5 mm at 6 months
(indicated by red rectangle)[ 9], significantly shifts ventrocranially
(p<0.001). At 48 months, the highest success rates were found for
tape position at 40–70 % of the urethral length and a tape–urethra
distance of 2–5m m( green square)
Table 2 Changes in tape functionality between 6 and 48 months after
surgery
Group I
(48months)
Group II
(48months)
Group III
(48months)
Total
Group I
(6 months)
13 3 6 22
Group II
(6 months)
23 0 5
Group III
(6 months)
0 0 14 14
Total 15 6 20 41
Int Urogynecol J (2010) 21:795–800 797was seen when the tape distance was <2 mm and was
significantly associated with obstructive complications.
A multifactorial regression analysis taking into account
all demographic and preoperative factors revealed no
influence of any of these factors on the women’s outcome.
The rate of obstructive complications increased from
12% (5/41) to 19% (8/41) between the 6- and 48-month
postoperative follow-ups. There was a change in the critical
minimum distance of the tape from the urethra below
which obstructive complications occurred. At the 6-month
follow-up, a tape distance of less than 3 mm was
associated with a significantly higher complication rate
(p<0.001). At the 48-month follow-up, all women with
obstructive complications had a tape–urethra distance of
less than 2 mm. The median tape distance in women with
obstructive complications was 1.3 mm. Patients who were
classified as cured had a significantly greater median tape–
urethra distance of 2.9 mm (p<0.001). Women with a less
than 2 mm distance had a 2.8-fold higher risk of
obstructive complications.
At the 6-month follow-up, a tape distance of less than
2 mm was measured in 14 patients; five of the patients
(36%) had obstructive complications. The VAS scores these
patients assigned to their degree of suffering were 6, 5, 0, 5,
and 3. The scores assigned at the 48-month follow-up were
0, 3, 0, 1, and 9, respectively. These scores were assigned
after conservative treatment and despite persistent symp-
toms. All patients in this subgroup had Group III tape
functionality.
In two women with new-onset obstructive complications
and proven tape displacement toward the urethra at the 48-
month follow-up, splitting of the TVT had to be recom-
mended after failure of medical treatment.
Figure 3 shows that a clear association exists between
recurrence and complication rates at 48 months and tape
functionality at the 6-month follow-up. Patients in whom
tape functionality was rated to be optimal at the 6-month
follow-up were found to have a 3.7-fold lower risk of
recurrent SUI and a significantly lower risk of mid-term
complications (p=0.016) at 48 months.
Discussion
Ultrasound is a simple and noninvasive imaging modality
that provides detailed information on the position of the
TVT relative to the urethra and changes in shape during
straining [8–11].
Fig. 2 Changes in tape shape in Groups I–III (tape functionality) by
baseline tape position at 48-month follow-up. The groups are
explained in the “Patients and methods” section
Fig. 3 Patients were assigned
to the groups based on tape
functionality at the 6-month
postoperative follow-up. The
figure shows cure and compli-
cation rates by group at
48 months
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show how these sonographically determined parameters
affect the success of surgery and the complication rate.
Note that the findings obtained with the TVT used in our
patients may not be transferable to other suburethral slings
made of different materials.
Our study has revealed specific ultrasound findings that
can be obtained if the tape is either too close to the urethra
or too far away and that these findings are associated with a
lower cure rate and higher rate of complications. Outcome
was best in women in whom US demonstrated the elastic
sling to lie parallel to the urethra at rest and assume a
transient C-shape during straining. We assume that this
ultrasound finding suggests tension-free orthotopic posi-
tioning of the tape and that this position makes optimal use
of the tape’s elasticity reserve, thereby ensuring sufficient
compression of the urethra during Valsalva’s maneuver. Our
data also indicate that if ultrasound shows this tape
functionality at 6-month, the patient can expect mid-term
cure and a low mid-term complication rate.
However, if the shape of the TVT remains unchanged
during straining (Group II), women continue to experi-
ence involuntary loss of urine during stress. We attribute
failure in these cases to the fact that the urethra is not
sufficiently pressed into the prolene tape or not at all,
which is not related to absolute tape–urethra distance
alone but also to urethral mobility [10] (see Fig. 2). In
these cases, the elasticity reserve of the tape is not fully
exploited and tape position can be characterized as loose
rather than tension-free.
Those cases where the sonographic findings show the
tape to be C-shaped already at rest are associated with a
higher rate of mid-term complications, confirming our
earlier observations [9]. A permanent C-shape may suggest
that the tape has been placed with too much tension
intraoperatively, resulting in permanent folding at the
midline. In this setting, the tape has no elasticity reserve
and cannot change its shaping during straining.
Moreover, our results suggest that tape position signif-
icantly affects outcome, which is in disagreement with the
results published by Dietz et al. in 2004 [12]. In their study,
Dietz et al. used the symphysis pubis as reference and
found the sonographically determined tape position to vary
in a range from 30 mm above to 12.7 mm below the
symphysis. However, the tape directly affects the urethra
and we therefore think that the urethra is also the most
suitable reference for determining the optimal TVT posi-
tion. This may in part explain the different conclusions
drawn by Dietz et al. Moreover, Dietz et al. do not take into
account urethral length and its physiological variation. We
think that urethral length is a central factor for optimal TVT
placement since the procedure aims at supporting the mid-
third of the urethra during straining [13]. Our findings
suggest that optimal outcome is achieved if the TVT is
placed at 40% to 70% of the urethral length. These results
also support the pathophysiological insights of Ulmsten and
Petros [14].
In another study published in 2003, Dietz et al.
demonstrated gradual upward displacement of the TVT
relative to the symphysis pubis over a 17-month period
[15]. Our mid-term results show a significant change in
the tape position relative to the length of the urethra
toward the bladder neck as well as a significant shortening
of the tape–urethra distance during the 48-month follow-
up period. Both changes can be attributed to a gradual
prolapse of the anterior compartment, resulting in a
relative shift of the urethra. Concomitantly, the TVT is
displaced ventrocranially.
Interestingly, the change in tape–urethra distance and
tape position did not adversely affect patient satisfaction
with outcome. The patients who were satisfied at the 6-
month follow-up when the tape–urethra distance was 3 mm
were also satisfied at 48 months despite a decrease in tape
distance to 2 mm. The optimal tape–urethra distance
decreased from 3–5 mm to 2.5 mm during the follow-up
period of our study. In contrast, patients with a tape–urethra
distance of 2 mm were already more dissatisfied at
6 months. These observations suggest that the range of
optimal tape positions increases over time through habitu-
ation or adaptation of the urethral tissue to the TVT. Similar
observations regarding complications were reported by
Nilsson et al. in 2008, who did not find an increase in
complications even after 11 years [16].
Predictors of mid-term outcome after suburethral sling
procedures are still a matter of scientific debate [17–20].
The mid-term data we presented here suggest that sono-
graphic evaluation of tape functionality at 6 months
provides clues to mid-term outcome and complications.
Optimal tape functionality at 6 months is a good predictor
of mid-term therapeutic success. The pilot character of our
study is a potential weakness, and our findings need to be
confirmed in larger, prospective studies, which are already
planned.
Summary
TVT insertion is a reliable and successful therapeutic option
that ensures mid-term cure of stress urinary incontinence
[16, 21]. The mid-term results presented here show that the
position of the tape relative to the urethra as determined by
introital ultrasound affects both outcome and the occurrence
of complications. Ventrocranial displacement of the tape
was observed to occur over time. Outcome was optimal in
our study if the tape was position between 40% and 70% of
the urethral length. Obstructive complications were signif-
Int Urogynecol J (2010) 21:795–800 799icantly more common when the tape–urethra distance was
<2 mm. The optimal range of the tape–urethra distance
increased to 2–5 mm at the 48-month follow-up compared
with the 6-month follow-up and is attributable to habitua-
tion. Tape functionality was identified as another crucial
factor. Optimal tape functionality at 6-month follow-up was
a good predictor of mid-term therapeutic success.
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